EZH2 and neoplasm: Another study found that reducing H3K27me3 levels via the inhibition of EZH2 activity in MDA-MB-468, BT20, and HCC38 triple-negative breast cancer cells promotes a drug-tolerant state, and treatment with a KDM6A/B inhibitor upon chemotherapy treatment reduces the number of drug-resistant cells and delays tumor recurrence in mouse models [114].